- Home
- DOMO vs IMTX Comparison
DOMO vs IMTX Comparison
Compare DOMO & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- IMTX
- Stock Information
- Founded
- DOMO 2010
- IMTX N/A
- Country
- DOMO United States
- IMTX Germany
- Employees
- DOMO 888
- IMTX N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOMO Technology
- IMTX Health Care
- Exchange
- DOMO Nasdaq
- IMTX Nasdaq
- Market Cap
- DOMO 562.5M
- IMTX 653.9M
- IPO Year
- DOMO 2018
- IMTX N/A
- Fundamental
- Price
- DOMO $14.97
- IMTX $5.93
- Analyst Decision
- DOMO Hold
- IMTX Strong Buy
- Analyst Count
- DOMO 6
- IMTX 4
- Target Price
- DOMO $12.17
- IMTX $14.67
- AVG Volume (30 Days)
- DOMO 662.1K
- IMTX 758.4K
- Earning Date
- DOMO 08-28-2025
- IMTX 08-12-2025
- Dividend Yield
- DOMO N/A
- IMTX N/A
- EPS Growth
- DOMO N/A
- IMTX N/A
- EPS
- DOMO N/A
- IMTX N/A
- Revenue
- DOMO $317,052,000.00
- IMTX $155,801,989.00
- Revenue This Year
- DOMO $1.71
- IMTX N/A
- Revenue Next Year
- DOMO $2.43
- IMTX $1.92
- P/E Ratio
- DOMO N/A
- IMTX N/A
- Revenue Growth
- DOMO N/A
- IMTX 93.56
- 52 Week Low
- DOMO $6.01
- IMTX $3.30
- 52 Week High
- DOMO $15.42
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- DOMO 67.11
- IMTX 55.46
- Support Level
- DOMO $14.20
- IMTX $5.50
- Resistance Level
- DOMO $15.42
- IMTX $5.82
- Average True Range (ATR)
- DOMO 0.79
- IMTX 0.27
- MACD
- DOMO 0.03
- IMTX -0.03
- Stochastic Oscillator
- DOMO 85.02
- IMTX 50.49
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.